BUND: Tagfaltermonitoring in Höxter

In einer Kulturlandschaft wie am Stadtrand von Höxter konnten besonders in den Sommermonaten Juli bis September viele Tagfalter beobachtet werden. Dabei wurden an diesem Ort 13 verschiedene Arten gesichtet. Die bekannten und weit verbreiteten Arten wie die "Weißlinge" und der "Kleine Fuchs" waren auch hier am häufigsten zu sehen. Aber auch das "Große Ochsenauge" war überaus zahlreich vertreten. Die nicht ganz so häufigen, aber noch nicht bedrohten Arten "Kleines Wiesenvögelchen", "Hauhechelbläuling" und "Schornsteinfeger" waren mehrmals anzutreffen. Besonders geschützte Arten wurden nicht gesehen. Die in der Literatur angegebenen jahreszeitlichen Flugzeiten für die Falter konnten grob nachvollzogen werden. Vor allem an Abschnitt 6 konnte deutlich beobachtet werden, dass eine radikale Mahd, insbesondere der Brennnesselbestände, die Anzahl der Schmetterlinge erheblich reduzierte

Abenteuer Faltertage am Taubenborn 2006 und 2007

Eine vom Aussterben bedrohte Art ist der Kaisermantel (Rote Liste Stufe 3 in NRW). Auch das Kleine Wiesenvögelchen steht auf der Vorwarnliste der Roten Liste der vom Aussterben bedrohten Arten. So kommen im Taubenborn schützenswerte Tagfalter und insgesamt eine bemerkenswerte Anzahl von Arten vor. Nur wenn wir die Schmetterlinge regelmäßig beobachten, sie selbst und ihren Lebensraum kennen, können wir sie vor dem Aussterben bewahren. Die Exkursion am 5. Mai 2007 fand reges Interesse bei Groß und Klein (Abb. 5). Die Teilnehmer erhielten kleine Faltblätter mit Abbildungen der oben genannten zehn Arten als Bestimmungshilfe und wurden dazu aufgefordert, an einem beliebigen Tag zu Hause oder auf einem Spaziergang nach diesen Arten zu suchen und die Ergebnisse an den BUND zu melden. Wünschenswert wäre, wenn sich noch mehr Menschen für eine regelmäßige Schmetterlingsbeobachtung bereit fänden

O-GlcNAcase contributes to cognitive function in Drosophila

Contains fulltext : 219183.pdf (publisher's version ) (Open Access

"Mein Herz hat mich nie im Stich gelassen!" Innere Bilder im Prozess der Inkorporation einestransplantierten Herzens

Harvey's modern insight into the archetypal idea of the heart as the centre of blood motion transforms the heart into a machine which becomes a spare part interchangeable from any chest to any other {[}Hillman]. As we try to show in the case of Elmar, a 41-year-old technician 2 years after his transplantation, the possibilities of cardiac surgery and its archetypal foundations do not exclude a personalized and symbolic vision of both the `old' heart and the `new' one. Intrapersonal and therapeutic issues of this `inter-cardiac conflict' are discussed

Intravitreal Anti-VEGF Drugs and Signals of Dementia and Parkinson-Like Events: Analysis of the VigiBase Database of Spontaneous Reports

Introduction: Since vascular endothelial growth factor (VEGF) regulates several aspects of the central nervous system, particularly in dopaminergic neurons, VEGF inhibitors may be linked to Parkinson-like events and dementia, or variants of these diseases. Two recent case reports have found a potential link between intravitreal anti-VEGF use and Parkinson’s disease (PD) and dementia. Aim: To evaluate disproportionality in a large spontaneous reporting database concerning intravitreal anti-VEGF drugs and PD or dementia, and related conditions. Methods: Using VigiBase, individual case safety reports (ICSRs) attributed to intravitreal ranibizumab, aflibercept, pegaptanib, and bevacizumab were identified from 2010 to 2016. Within Standardised Narrow Medical Dictionary for Regulatory Activities (MedDRA®) Queries (SMQs) for “Parkinson-like events” and “Dementia,” suspected events were identified using preferred terms (PTs). The Proportional Reporting Ratio (PRR) was estimated with the lower 95% confidence intervals (CIs) for all drug-event pairs with ≥3 suspected events. The vigiGrade completeness score was reported for the ICSRs. The analyses were repeated, including only persons aged 65 and over. Results: Out of 18.9 million ICSRs, 7,945 (0.004%) concerned intravitreal anti-VEGF drugs. Of these, 27 (0.34%) were identified concerning the SMQs “Dementia” (N = 17, 62.96%) and “Parkinson-like events” (N = 10, 37.94%) in persons of all ages. Among persons age 65 and over, 4,758 (59.88% of relevant ICSRs) ICSRs were identified for anti-VEGF drugs. When restricting disproportionality analysis to persons aged 65 and over, no disproportionality was seen for any of the drug-event pairs at the level of SMQ. However, on analysing disproportionality by PT, a potential signal emerged for intravitreal ranibizumab and Parkinson’s disease [N = 6 ICSRs; PRR: 3.05 (95% CI: 1.36-6.81)]. In general, the vigiGrade completeness score was low for all the ICSRs of interest, as no ICSR had a score >0.8. Conclusion: Present findings suggest a potential signal for Parkinson’s disease related to intravitreal ranibizumab. This is supported by several biologically plausible mechanisms but requires confirmation through pharmacoepidemiological studies, especially because of the low number of cases

Long-Term Intravitreal Ranibizumab as a Potential Additional Risk Factor for Neurodegeneration in Parkinson's Disease: A Case Report.

In November 2012, a 72-year old patient was diagnosed with left eye wet age-related macular degeneration. The patient received three monthly intravitreal injections of ranibizumab, with complete resolution of retinal hemorrhage and edema and reinstatement of visual acuity. In May 2015, symptomatic relapse was detected. The patient was again treated with intravitreal ranibizumab, with overall six injections till the end of February 2016. In May 2016, the patient complained of left hand resting tremor, bradykinesia, and postural rigidity of head and trunk. A diagnosis of clinically established PD was made based on new criteria of the Movement Disorders Society. Single Photon Emission Computerized Tomography of the Dopamine Transporter with (123I) ioflupane documented a low Dopamine Transporter (DAT) uptake mostly in the right striatum. Due to the documented protective role of vascular endothelial growth factor (VEGF) on the dopaminergic neurons, intensive intravitreal injections of the anti-VEGF agent ranibizumab may have played as an additional risk factor accelerating the neurodegeneration process related to PD and the onset of the related clinical signs and symptoms

tRNA Dysregulation in Neurodevelopmental and Neurodegenerative Diseases.

Transfer RNAs (tRNAs) decode messenger RNA codons to peptides at the ribosome. The nuclear genome contains many tRNA genes for each amino acid and even each anticodon. Recent evidence indicates that expression of these tRNAs in neurons is regulated, and they are not functionally redundant. When specific tRNA genes are nonfunctional, this results in an imbalance between codon demand and tRNA availability. Furthermore, tRNAs are spliced, processed, and posttranscriptionally modified. Defects in these processes lead to neurological disorders. Finally, mutations in the aminoacyl tRNA synthetases (aaRSs) also lead to disease. Recessive mutations in several aaRSs cause syndromic disorders, while dominant mutations in a subset of aaRSs lead to peripheral neuropathy, again due to an imbalance between tRNA supply and codon demand. While it is clear that disrupting tRNA biology often leads to neurological disease, additional research is needed to understand the sensitivity of neurons to these changes

Impaired protein translation in Drosophila models for Charcot–Marie–Tooth neuropathy caused by mutant tRNA synthetases

Dominant mutations in five tRNA synthetases cause Charcot–Marie–Tooth (CMT) neuropathy, suggesting that altered aminoacylation function underlies the disease. However, previous studies showed that loss of aminoacylation activity is not required to cause CMT. Here we present a Drosophila model for CMT with mutations in glycyl-tRNA synthetase (GARS). Expression of three CMT-mutant GARS proteins induces defects in motor performance and motor and sensory neuron morphology, and shortens lifespan. Mutant GARS proteins display normal subcellular localization but markedly reduce global protein synthesis in motor and sensory neurons, or when ubiquitously expressed in adults, as revealed by FUNCAT and BONCAT. Translational slowdown is not attributable to altered tRNA[superscript Gly] aminoacylation, and cannot be rescued by Drosophila Gars overexpression, indicating a gain-of-toxic-function mechanism. Expression of CMT-mutant tyrosyl-tRNA synthetase also impairs translation, suggesting a common pathogenic mechanism. Finally, genetic reduction of translation is sufficient to induce CMT-like phenotypes, indicating a causal contribution of translational slowdown to CMT.National Institutes of Health (U.S.) (Grant GM17151